Porphyria News and Research

RSS
Researchers describe the impact of chronic hepatitis D on parts of the immune system

Researchers describe the impact of chronic hepatitis D on parts of the immune system

New research opens the way for tailored cancer drugs

New research opens the way for tailored cancer drugs

Study finds low relapse risk in young patients with Hodgkin lymphoma

Study finds low relapse risk in young patients with Hodgkin lymphoma

New acute porphyria treatment shows promising results in clinical study

New acute porphyria treatment shows promising results in clinical study

New pre-clinical research shows utility of mRNA platform to treat rare metabolic disorders

New pre-clinical research shows utility of mRNA platform to treat rare metabolic disorders

Alnylam announces positive results from Phase 3 Study of givosiran for treating acute hepatic porphyria

Alnylam announces positive results from Phase 3 Study of givosiran for treating acute hepatic porphyria

Wrecked and retching: Obscure vomiting illness linked to long-term pot use

Wrecked and retching: Obscure vomiting illness linked to long-term pot use

Newly-discovered mutation highlights complex genetic network that underpins blood disorder

Newly-discovered mutation highlights complex genetic network that underpins blood disorder

Rare genetic variations linked to severe porphyria

Rare genetic variations linked to severe porphyria

Latest and final review of health problems related to Agent Orange exposure during Vietnam War

Latest and final review of health problems related to Agent Orange exposure during Vietnam War

Afamelanotide treatment improves quality of life in people with erythropoietic protoporphyria

Afamelanotide treatment improves quality of life in people with erythropoietic protoporphyria

New Internet tool may help analyze genes based on their evolutionary profile

New Internet tool may help analyze genes based on their evolutionary profile

New gene therapy for Acute Intermittent Porphyria

New gene therapy for Acute Intermittent Porphyria

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Alnylam initiates Phase II study with ALN-TTRsc for treatment of ATTR

Alnylam initiates Phase II study with ALN-TTRsc for treatment of ATTR

New test to help physicians identify patients with most lethal forms of triple-negative breast cancer

New test to help physicians identify patients with most lethal forms of triple-negative breast cancer

Alnylam presents new pre-clinical data with ALN-AT3 for treatment of hemophilia and RBD

Alnylam presents new pre-clinical data with ALN-AT3 for treatment of hemophilia and RBD

Tackling orphan diseases: an interview with Damian Marron, CEO, TxCell

Tackling orphan diseases: an interview with Damian Marron, CEO, TxCell

Alnylam advances Development Candidate for ALN-AS1 for treatment of hepatic porphyrias

Alnylam advances Development Candidate for ALN-AS1 for treatment of hepatic porphyrias

FDA grants Orphan Drug Designation to Alnylam ALN-AT3 for treatment of hemophilia B

FDA grants Orphan Drug Designation to Alnylam ALN-AT3 for treatment of hemophilia B